Market Overview

Vetr Upgrades Valeant After Price Dips

Share:
Related VRX
TD Ameritrade Traders Adopt Some Old And New Approaches To The Trade War Market In June's IMX
Investor Movement Index June Summary

The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE: VRX), from 4 stars (Buy), issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade was largely positive, with 80 percent of Vetr user ratings bullish.

Share price In Valeant is back on the uptrend after dipping below $17 earlier in the week after hitting a four-month high of $17.75. The stock closed Thursday's session up, but still below that high at $17.65

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target on Valeant is up at $22.46, which is still below the average analyst price target of $24.58. Valeant Pharmaceuticals is a popular stock on Vetr as more than 2 percent of users are holding VRX in their watch-lists.

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2018TD SecuritiesDowngradesBuyHold
Jun 2018BarclaysUpgradesEqual-WeightOverweight
May 2018MizuhoUpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General

 

Related Articles (VRX)

View Comments and Join the Discussion!